Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study

Table 2 HRQoL scores for adults over the course of the study

	U.S. general population [8, 9]	N	Baseline	n	End of part 1	Change from baseline at end of part 1	n	End of part 3	Change from baseline at end of part 3
FACIT-F	43.6	26	27.4 ± 13.0	24	40.6 ± 12.0	13.5^a	26	39.5 ± 14.7	12.2^a
SF-36 PCS	50.0	23	41.0 ± 9.6	20	51.0 ± 8.3	9.5^a	22	48.5 ± 12.6	8.2^a
SF-36 MCS	50.0	23	43.1 ± 12.3	20	47.3 ± 13.4	3.6	22	48.9 ± 12.4	6.3^a
HAQ	NA	26	0.41 ± 0.63	25	0.17 ± 0.40	-0.26^a	26	0.27 ± 0.45	-0.14

Values are expressed as mean ± SD. ^ap value < 0.05. FACIT-F, functional assessment of chronic illness therapy- fatigue; HAQ, health assessment questionnaire; MCS, mental component summary; NA, not available; PCS, physical component summary; SF-36, 36-item Short-Form Health Survey.

ISSN: 1478-6362